Mistreatment of women during childbirth and postpartum depression: secondary analysis of WHO community survey across four countries.


Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
08 2023
Historique:
received: 05 01 2023
accepted: 25 06 2023
medline: 25 8 2023
pubmed: 24 8 2023
entrez: 23 8 2023
Statut: ppublish

Résumé

Postpartum depression (PPD) is a leading cause of disability globally with estimated prevalence of approximately 20% in low-income and middle-income countries. This study aims to determine the prevalence and factors associated with PPD following mistreatment during facility-based childbirth. This secondary analysis used data from the community survey of postpartum women in Ghana, Guinea, Myanmar and Nigeria for the WHO study, 'How women are treated during facility-based childbirth'. PPD was defined using the Patient Health Questionnaire (PHQ-9) tool. Inferential analyses were done using the generalised ordered partial proportional odds model. Of the 2672 women, 39.0% (n=1041) developed PPD. 42.2% and 5.2% of mistreated women developed minimal/mild PPD and moderate/severe PPD, respectively. 43.0% and 50.6% of women who experienced verbal abuse and stigma/discrimination, respectively developed minimal/mild PPD. 46.3% of women who experienced physical abuse developed minimal/mild PPD while 7.6% of women who experienced stigma/discrimination developed moderate/severe PPD. In the adjusted model, women who were physically abused, verbally abused and stigma/discrimination compared with those who were not were more likely to experience any form of PPD ((OR: 1.57 (95% CI 1.19 to 2.06)), (OR: 1.42 (95% CI 1.18 to 1.69)) and (OR: 1.69 (95% CI 1.03 to 2.78))), respectively. Being single and having higher education were associated with reduced odds of experiencing PPD. PPD was significantly prevalent among women who experienced mistreatment during childbirth. Women who were single, and had higher education had lower odds of PPD. Countries should implement women-centred policies and programmes to reduce mistreatment of women and improve women's postnatal experiences.

Sections du résumé

BACKGROUND
Postpartum depression (PPD) is a leading cause of disability globally with estimated prevalence of approximately 20% in low-income and middle-income countries. This study aims to determine the prevalence and factors associated with PPD following mistreatment during facility-based childbirth.
METHOD
This secondary analysis used data from the community survey of postpartum women in Ghana, Guinea, Myanmar and Nigeria for the WHO study, 'How women are treated during facility-based childbirth'. PPD was defined using the Patient Health Questionnaire (PHQ-9) tool. Inferential analyses were done using the generalised ordered partial proportional odds model.
RESULTS
Of the 2672 women, 39.0% (n=1041) developed PPD. 42.2% and 5.2% of mistreated women developed minimal/mild PPD and moderate/severe PPD, respectively. 43.0% and 50.6% of women who experienced verbal abuse and stigma/discrimination, respectively developed minimal/mild PPD. 46.3% of women who experienced physical abuse developed minimal/mild PPD while 7.6% of women who experienced stigma/discrimination developed moderate/severe PPD. In the adjusted model, women who were physically abused, verbally abused and stigma/discrimination compared with those who were not were more likely to experience any form of PPD ((OR: 1.57 (95% CI 1.19 to 2.06)), (OR: 1.42 (95% CI 1.18 to 1.69)) and (OR: 1.69 (95% CI 1.03 to 2.78))), respectively. Being single and having higher education were associated with reduced odds of experiencing PPD.
CONCLUSION
PPD was significantly prevalent among women who experienced mistreatment during childbirth. Women who were single, and had higher education had lower odds of PPD. Countries should implement women-centred policies and programmes to reduce mistreatment of women and improve women's postnatal experiences.

Identifiants

pubmed: 37612033
pii: bmjgh-2023-011705
doi: 10.1136/bmjgh-2023-011705
pmc: PMC10450127
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© World Health Organization 2023. Licensee BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMJ Glob Health. 2020 Nov;5(11):
pubmed: 33219000
J Psychiatr Pract. 2005 Sep;11(5):353-8
pubmed: 16184076
J Affect Disord. 2019 Sep 1;256:441-447
pubmed: 31252237
J Midwifery Womens Health. 2020 Jan;65(1):96-108
pubmed: 31970924
J Affect Disord. 2006 Nov;96(1-2):89-93
pubmed: 16857265
Front Public Health. 2019 Oct 24;7:295
pubmed: 31709213
Afr Health Sci. 2020 Dec;20(4):1943-1954
pubmed: 34394261
J Affect Disord. 2020 Aug 1;273:391-401
pubmed: 32560934
Malays J Med Sci. 2021 Aug;28(4):71-86
pubmed: 34512132
Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):345-59
pubmed: 20633738
Psychiatr Clin North Am. 2011 Mar;34(1):53-65
pubmed: 21333839
Annu Rev Clin Psychol. 2015;11:99-137
pubmed: 25822344
Am J Obstet Gynecol. 2015 Feb;212(2):229.e1-7
pubmed: 25218957
Reprod Health Matters. 2018;26(53):70-87
pubmed: 30152268
J Affect Disord. 2009 Feb;113(1-2):109-17
pubmed: 18614241
Arch Psychiatr Nurs. 2005 Dec;19(6):281-90
pubmed: 16308128
Psychol Russ. 2021 Mar 20;14(1):28-38
pubmed: 36950315
Women Birth. 2022 Feb;35(1):e28-e40
pubmed: 33707143
PLoS Med. 2015 Jun 30;12(6):e1001847; discussion e1001847
pubmed: 26126110
Lancet. 2019 Nov 9;394(10210):1750-1763
pubmed: 31604660
Bull World Health Organ. 2012 Feb 1;90(2):139G-149G
pubmed: 22423165
PLoS One. 2020 Apr 22;15(4):e0231415
pubmed: 32320424
Depress Anxiety. 2015 Feb;32(2):108-19
pubmed: 24272979
Int J Gynaecol Obstet. 2013 Mar;120(3):228-31
pubmed: 23228821
Reprod Health. 2015 Jul 22;12:60
pubmed: 26198988
Women Birth. 2021 Sep;34(5):477-486
pubmed: 33067128
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Health Hum Rights. 2020 Jun;22(1):251-264
pubmed: 32669805

Auteurs

Chris Guure (C)

Department of Biostatistics, School of Public Health, University of Ghana, Legon, Ghana.
Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Philomina Akandity Aviisah (PA)

Department of Health Information Management, College of Health and Well-Being, Kintampo, Ghana.

Kwame Adu-Bonsaffoh (K)

Department of Obstetrics Gynaecology, University of Ghana Medical School, University of Ghana, Accra, Ghana.

Hedieh Mehrtash (H)

Department of Sexual and Reproductive Health and Research, including UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), World Health Organization, Geneve, Switzerland.

Adeniyi Kolade Aderoba (AK)

Reproductive and Maternal Health, and Healthy Ageing Unit, Universal Health Coverage - Life Course Cluster, World Health Organization Regional Office for Africa, Brazzaville, Democratic Republic of Congo.
Department of Obstetrics and Gynaecology, Mother and Child, State Specialist Hospital, Akure, Nigeria.

Theresa Azonima Irinyenikan (TA)

Department of Obstetrics and Gynecology, Faculty of Clinical Sciences, University of Medical Sciences, Akure, Ondo State, Nigeria.

Mamadou Dioulde Balde (MD)

Cellulle de Recherche en Sante de la Reproduction en Guinee (CERREGUI), Conakry, Guinea.

Olusoji Adeyanju (O)

Adeoyo Maternity Teaching Hospital, Ibadan, Nigeria.

Thae Maung Maung (TM)

Department of Medical Research, Ministry of Health and Sports, Yangon, Myanmar.

Özge Tunçalp (Ö)

Department of Sexual and Reproductive Health and Research, including UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), World Health Organization, Geneve, Switzerland.

Ernest Maya (E)

Department of Population, Family & Reproductive Health, School of Public Health, University of Ghana, Legon-Accra, Ghana emaya@ug.edu.gh.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH